Innovate UK provides grant for cell therapy preservation hydrogel

By Vassia Barba

- Last updated on GMT

(Image: Getty/microgen)
(Image: Getty/microgen)

Related tags Innovate UK Cell therapy Cell and gene therapy catapult Logistics

Atelerix to work on the development of gel stabilisation technologies enabling room temperature storage of Rexgenero’s cell therapy candidate, under an Innovate UK grant.

Founded in 2017 as a spinout from Newcastle University, UK, and with the support of the UK Innovation & Science Seed Fund, Atelerix has developed a technology that enables the storage and transport of viable human cells at temperatures between 4°C and 25°C.

This is achieved through encapsulation of the cells in a natural hydrogel, which preserves their functional viability ‘up to weeks’, according to the company. When needed, the cells are recovered with the addition of a ‘cell-friendly’ buffer.

The company has been awarded a grant of £267,000 ($324,110) from Innovate UK, which will be used to apply the preservation technology on REX-001, the lead cell therapy candidate of Rexgenero, a clinical-stage cell therapies developer, headquartered in the UK.

REX-001 is a potential treatment for chronic limb-threatening ischaemia (CLI) in diabetic patients, currently in Phase III clinical development. It consists of autologous bone marrow-derived white blood cells, extracted from a patient’s own bone marrow.

By extending the shelf-life of the candidate, the technology is expected to help Rexgenero “ensure that hospitals have the flexibility for less rigid scheduling of operating theatres, making it easier to treat patients and therefore enabling as many patients as possible to be treated,”​ the company’s CEO, Joe Dupere, said in a statement.

He added that preserving the product in room temperature also widens the manufacturing options and “should help to drive down cost.”

Although the project will initially focus on REX-001, the technology is expected to have broad applicability to a wide range of other cell therapies, Atelerix stated.

“The critical logistics of getting viable cell therapies to the patient are often overlooked,” ​Mick McLean, CEO of Atelerix, commented, adding that the technology is expected to open up an ‘entirely new’ approach for this sector.

The project will be additionally supported by the Cell and Gene Therapy Catapult center.

Related news

Show more

Related products

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 22-Mar-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 21-Feb-2023 | Product Brochure

Deliver safe and stable products to your patients with the help of Catalent Biologics' Limoges, France site, a European Center of Excellence for early-phase...

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Related suppliers

Follow us


View more